Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback